SG11201509368PA - Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna - Google Patents

Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Info

Publication number
SG11201509368PA
SG11201509368PA SG11201509368PA SG11201509368PA SG11201509368PA SG 11201509368P A SG11201509368P A SG 11201509368PA SG 11201509368P A SG11201509368P A SG 11201509368PA SG 11201509368P A SG11201509368P A SG 11201509368PA SG 11201509368P A SG11201509368P A SG 11201509368PA
Authority
SG
Singapore
Prior art keywords
feeder
human
stem cells
pluripotent stem
messenger rna
Prior art date
Application number
SG11201509368PA
Inventor
Jiwu Wang
Original Assignee
Allele Biotechnology & Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allele Biotechnology & Pharmaceuticals Inc filed Critical Allele Biotechnology & Pharmaceuticals Inc
Publication of SG11201509368PA publication Critical patent/SG11201509368PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201509368PA 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna SG11201509368PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/893,166 US10155929B2 (en) 2012-05-13 2013-05-13 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
PCT/US2014/040362 WO2014190361A2 (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Publications (1)

Publication Number Publication Date
SG11201509368PA true SG11201509368PA (en) 2015-12-30

Family

ID=51939013

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202006695TA SG10202006695TA (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
SG11201509368PA SG11201509368PA (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202006695TA SG10202006695TA (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Country Status (8)

Country Link
US (1) US10155929B2 (en)
EP (2) EP2997130A4 (en)
JP (2) JP6971574B2 (en)
CN (1) CN105555949A (en)
HK (2) HK1222675A1 (en)
MX (2) MX2015015840A (en)
SG (2) SG10202006695TA (en)
WO (1) WO2014190361A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2691027C2 (en) 2011-12-05 2019-06-07 Фэктор Байосайенс Инк. Methods and preparations for transfection of cells
US10155929B2 (en) * 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US10119150B2 (en) 2012-05-13 2018-11-06 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
AU2013263101B2 (en) * 2012-05-13 2019-02-14 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
WO2013188679A1 (en) * 2012-06-13 2013-12-19 Stemgent, Inc. Methods of preparing pluripotent stem cells
RU2711249C2 (en) 2012-11-01 2020-01-15 Фэктор Байосайенс Инк. Methods and products for expression of proteins in cells
EP4249036A3 (en) 2014-01-31 2023-10-25 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
CA2950582C (en) * 2014-05-30 2020-09-22 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN105567642B (en) * 2016-02-01 2019-07-12 中国科学院生物物理研究所 A kind of preparation method of xeroderma pitmentosum human pluripotent stem cells
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
KR102546749B1 (en) * 2016-12-28 2023-06-22 교토후고리츠다이가쿠호진 Skeletal muscle cells and methods for their derivation
CN107142244B (en) * 2017-07-03 2019-12-20 广州润虹医药科技股份有限公司 Culture medium, application thereof and method for inducing transformation of pluripotent stem cells into mesenchymal stem cells
JP2021518331A (en) * 2018-03-13 2021-08-02 ザ・ボード・オブ・トラステイーズ・オブ・ザ・リーランド・スタンフオード・ジユニア・ユニバーシテイ Transient cell reprogramming for cell aging reversal
EP3806873A1 (en) * 2018-06-16 2021-04-21 Luigi Warren Reprogramming cells with synthetic messenger rna
EP3969571A4 (en) * 2019-05-14 2023-05-24 Aleph Farms Ltd. Pluripotent cell aggregates and use thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260432A (en) 1989-06-22 1993-11-09 Sloan-Kettering Institute For Cancer Research Human gamma retinoic acid receptor DNA
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
SG160248A1 (en) * 2008-09-18 2010-04-29 Agency Science Tech & Res Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells
EP2192174B1 (en) 2008-11-21 2015-11-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Reprogramming cells toward a pluripotent state
US20120207744A1 (en) 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
WO2011016588A1 (en) * 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
CN102190731B (en) * 2010-03-09 2016-01-27 中国科学院上海生命科学研究院 Multipotential stem cell is produced with manual transcription factor induction
US9725695B2 (en) * 2010-05-05 2017-08-08 The Regents Of The University Of California Stem cell defined media for xeno-free and feeder free conditions and uses thereof
WO2011142832A2 (en) 2010-05-13 2011-11-17 Whitehead Institute For Biomedical Research Stem cells derived under low oxygen conditions
WO2012012708A1 (en) 2010-07-22 2012-01-26 Regents Of The University Of Minnesota Induced pluripotent stem cells
AU2012246822B2 (en) * 2011-04-22 2017-05-25 Biomarin Technologies B.V. New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1)
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
EP2816893A1 (en) 2012-02-22 2014-12-31 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
US10155929B2 (en) 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
AU2013263101B2 (en) 2012-05-13 2019-02-14 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA

Also Published As

Publication number Publication date
CN105555949A (en) 2016-05-04
WO2014190361A2 (en) 2014-11-27
EP2997130A4 (en) 2017-03-01
US10155929B2 (en) 2018-12-18
EP2997130A2 (en) 2016-03-23
JP2021166553A (en) 2021-10-21
MX2015015840A (en) 2016-08-11
HK1222675A1 (en) 2017-07-07
US20130302295A1 (en) 2013-11-14
WO2014190361A3 (en) 2015-07-30
HK1224335A1 (en) 2017-08-18
JP6971574B2 (en) 2021-11-24
SG10202006695TA (en) 2020-08-28
JP2016521541A (en) 2016-07-25
MX2021005715A (en) 2021-07-21
EP3904504A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
HK1224335A1 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna rna
HK1204005A1 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna rna
IL241930B (en) Isolated naive pluripotent stem cells and methods of generating same
SG11201801549VA (en) Pluripotent stem cell production system
EP3334820C0 (en) Induced extended pluripotent stem cells, methods of making and using
HK1219975A1 (en) Cell lines for virus production and methods of use
SG11201507510PA (en) Isolation of non-embryonic stem cells and uses thereof
EP2968549A4 (en) Methods of cell culture
EP2971040A4 (en) Methods of cell culture
EP2971014A4 (en) Methods of cell culture
PT2981607T (en) Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
SG11201604584QA (en) In vitro production of foregut stem cells
EP2861612A4 (en) Methods of preparing pluripotent stem cells
EP3060650A4 (en) Culturing pluripotent stem cells
EP2904103A4 (en) Method for preparing induced pluripotent stem cells and its applications
HK1222200A1 (en) Method for preparing pluripotent stem cells
HK1219050A1 (en) Immunoprotective primary mesenchymal stem cells and methods
EP2948407A4 (en) Hydrogen production system and methods of using same
HK1222886A1 (en) Mammalian muscle-derived stem cells
EP2949746A4 (en) Method of subculturing pluripotent stem cells
HK1216904A1 (en) Liquid culturing of epithelial stem cells
SG11201510209SA (en) Cell populations, methods of transdifferention and methods of use thereof
SG11201503167XA (en) Method of efficiently establishing induced pluripotent stem cells
GB201303491D0 (en) Culture of leukemia initiating cells
SG10201800836YA (en) Method of identifying adipose stem cells